The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a ...
Jun 2, 2013
0
0
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher ...
Jun 2, 2013
0
0
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research ...
Jun 2, 2013
0
0
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented ...
Jun 1, 2013
0
0
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual ...
May 17, 2013
0
0
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
May 17, 2013
0
0
(HealthDay)—An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows.
May 16, 2013
0
1
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.
Mar 20, 2013
0
0
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
Feb 8, 2013
0
0
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Dec 24, 2012
0
0
